Thermo Fisher Scientific has launched its new library preparation innovation, Ion AmpliSeq HD technology, for targeted next-generation sequencing (NGS) oncology and genetic research applications.

The technology provides flexibility to clinical researchers to custom design gene panels without sacrificing the ultra-high sensitivity that is needed to find low-frequency variants in cell-free DNA (cfDNA) and highly heterogeneous solid tumour samples.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Thermo Fisher’s new Ion AmpliSeq HD technology enables custom design flexibility for single nucleotide variations (SNVs), small insertions/deletions (indels).

“The technology has also demonstrated application in inherited disease research, with potential use in infectious disease research, microbial studies, and gene expression analysis.”

It also enables flexibility for fusions and copy number variation (CNV) detection with a limit of detection (LOD) as low as ≤0.1 percent in blood samples.

Thermo Fisher Scientific clinical sequencing product management vice-president Andy Felton said: “As oncology research continues to evolve at a rapid pace, so has demand for advanced tools that can keep pace with the needs of our customers.

“We have built upon the knowledgebase from our market-leading AmpliSeq technology to now provide a solution that raises the bar for library prep by combining flexibility with ultra-high sensitivity.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The heightened sensitivity achieved with the new technology is enabled with molecular tags, while dual barcoding of the fragments of interest helps improve accuracy in fragment identification as well as sequencing using the Ion GeneStudio S5 Series instruments.

Ion AmpliSeq HD, which is similar to the original technology, also provides workflow improvements that reduce library preparation time to less than three hours.

The technology has also demonstrated application in inherited disease research, with potential use in infectious disease research, microbial studies, and gene expression analysis.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact